Treatment of ducks congenitally infected with the duck hepatitis B virus (DHBV) using the guanosine analogue ganciclovir resulted in prompt and profound inhibition of viral DNA replication in serum and liver. By the end of the treatment period all the replicative intermediates, except the supercoiled DNA form, could not be detected. Within 2 weeks of cessation of treatment viral replication returned and, in some cases, rebound occurred. Sequential treatment with prednisolone followed by ganciclovir also resulted in inhibition of viral replication and, even though relapse was observed after therapy was discontinued, the rebound phenomenon was reduced. Ganciclovir significantly and selectively inhibited DHBV DNA replication but may be more efficacious if used in combination with compounds targeted to the viral supercoiled DNA form.
Introduction
Infections with hepatitis B virus (HBV) constitute a global public health problem. There are estimated to be over 250 million chronic carriers world-wide, many of whom develop chronic active hepatitis, cirrhosis or primary hepatocellular carcinoma (Szmuness, 1978) . There is little effective therapy for chronic HBV infection other than the use of interferon-alpha (IFN-cx). Even so, in the most successful trials, the response rate in highly selected patients has rarely exceeded 40% (Alexander et aI., 1987) and relapses after 12 months are common. At present, a combination treatment of recombinant IFN-cx after immune stimulation provided by corticosteroid withdrawal appears to offer the most promising therapy for chronic HBV infection (PerriII0 et al., 1988) .
Duck hepatitis B virus (DHBV) has been used as a model of human HBV infection (Zuckerman, 1987) and several antiviral agents have now been evaluated in live ducks (Sherker et al., 1986) . In particular, the nucleoside analogue adenine arabinoside (Hirota et al., 1987) and the purine and pyrimidine 2' ,3' -dideoxynucleosides such as 2,6-diaminopurine 2' ,3' -dideoxyriboside (Leeet al., 1989) , 2' ,3' -dideoxycytidine (Kassianides et aI., 1989 ) and 3'azido-3'-deoxythymidine or zidovudine (Haritani et al., 1989) have been tested. The most effective agents appear to be the purine analogues (Lee et al., 1989) .
Ganciclovir (9-[2-hydroxy-1-(hydroxymethyl) ethoxymethyl] guanine), a congener of acyclovir, is a synthetic guanosine analogue which has proven useful in the management of cytomegalovirus infections, especially in patients with the acquired immune deficiency syndrome (AIDS) (Jacobson et al., 1987) . In a previous report from our laboratory (Locarnini et al., 1989) , we demonstrated that ganciclovir could significantly inhibit human HBV DNA replication in patients also infected with the human immunodeficiency virus (HIV). In addition, Civitico et al. (1990) have demonstrated that ganciclovir effectively inhibited DHBV DNA replication in persistently infected hepatocytes in vitro and this observation has been confirmed by Yokota et al. (1990) .To gain a greater insight into the mechanism of action of ganciclovir and its possible use as an anti-hepadnaviral agent, we tested this compound alone and in combination with steroid withdrawal using the congenitally infected DHBV model system.
Results
All the ducks survived the treatment without any apparent ill effects. The laboratory markers of liver, renal and haematological function did not change during treatment A plasma was approximately 0.1 f.LM and reproducibility of repeat assays was within ±5%. Single intraperitoneal (i.p.) doses produced peak plasma concentrations of about 13 f.LM (ganciclovir dose 5 mg/kg) and 20 f.LM (ganciclovir dose 15mg/kg) after 60 or 60-120 min, respectively. Half-lives of 1.5 h (lower dose) and 2.5 h (higher dose) were estimated from the concentration-time curves (Fig. 1C) . A much greater variation in plasma concentrations was observed after the higher ganciclovir dose.
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Effect of ganciclavir on serum DHBV DNA levels Dot-blot hybridization analysis of serum DHBV DNA levels in the placebo-treated congenitally infected ducks showed that although there were some minor fluctuations during the study period, there was no significant change in the level of DHBV DNA (results not shown). In contrast, all the ducks treated with ganciclovir showed a rapid decrease in serum DHBV DNA levels (Fig. 2 ). Ducks treated with the lower dose regime (Fig. 2 , ducks A, Band C) appeared to respond more rapidly and the effect on the serum level of DHBV DNA appeared to be greater than in ducks treated with the higher dose regime (Fig. 20, E and F) . However, the pre-treatment viraemias in the higher dose group displayed a greater level of DHBV DNA present. In serum samples collected at the end of treatment, little or no DHBV DNA was detected by the conventional hybridization assay (Fig. 2, lane 4) .
Prednisolone treatment for 2 weeks had little consistent effect on DHBV DNA, but all three ducks showed a significant response after 3 weeks of ganciclovir therapy and during the study period; treated birds showed no significant weight variation compared to placebo or untreated control animals (results not shown). 
Gancicwvifpharmacakmeilcs
Plasma ganciclovir levels were monitored by highpressure liquid chromatography (HPLC). Under the conditions used, ganciclovir eluted with a retention time of 3.5 min and was well resolved from other UV-absorbing components. Each analysis was complete within 10 min ( Fig. 1A and B ). The detection limit of ganciclovir in duck Lane 1 shows pre-treatment (5 weeks of age) levels. For ducks A-F, lanes 2-4 refer to 3 weeks of treatment, and lanes 5 and 6 the 2-weekly follow-up serum. samples after treatment had finished. For ducks G-I, lanes 2 and 3 cover the 2 weeks of prednisolone therapy followed by ganciclovir (lanes 4-6) treatment, and then finally the 2 weekly followups (lanes 7 and 8). Ducks C, F and 1were killed at the end of treatment and the remaining ducks 4 weeks later. NT, not tested. ( Fig. 2G , H, I, lanes 4,5, and 6). In both the lower and the higher dose ganciclovir regimes, the level of viraemia rebounded ( Fig. 2A, B , 0, E, lane 5) to greater than pre-treatment levels within 2 weeks of cessation of therapy. This rebound phenomenon was not observed in follow-up samples obtained from ducks treated with prednisolone and ganciclovir ( Fig. 2G and H, lane 7). The course of ganciclovir treatments failed to produce any consistent or significant reduction in the level of circulating duck hepatitis B surface antigen (DHBsAg), as detected by solid-phase radioimmunoassay (SPRIA) (results not shown).
Effect of ganciclovir on liver DHBV DNA levels
The amount of viral DNA in the end of treatment and I Ganciclovir therapy for hepatitis B virus 109 follow-up'Ilver samples was examined by semi-quantitative dot-blot analysis (Fig. 3 ). The level of DHBV DNA per cell was estimated from the DHBV DNA standards ( Fig. 3 , duck K) (Jilbert et al., 1988) and the results are shown in Table 1 . After treatment with both ganciclovir regimes (Fig. 3, ducks C and D) , the viral DNA load in the liver was reduced to 25 viral genome equivalents {VGE)/cell from 360 VGE/cell (Fig. 3A , Band G, 5-week, 8-week and 12-week-old control ducks). Prednisolone treatment alone for 2 weeks reduced the level slightly ( Fig. 3 , row H; Table 1 ) and, when followed by ganciclovir treatment, this also resulted in a significant reduction to 60 VGE/cell ( Fig  31) . However, in all cases there was a significant increase in viral DNA after therapy ceased. In follow-up liver specimens obtained from ducks on either the lower dose or higher dose, the levels of viral DNA were greater than observed pre-treatment ( Fig. 3E and F). Analysis of liver tissue from the combined treatment regime of prednisolone and ganciclovir showed a relapse in levels of DHBV DNA rather than a rebound in the follow-up period ( Fig.3J ; Table 1 ), consistent with the results in serum.
The various replicative forms of DHBV DNA found in the liver were examined after Southern blot hybridization of total liver DNA ( Fig. 4 ). In this analysis there was no evidence of integration of DHBV DNA into the host cell genome. The relaxed circular (RC), double-stranded linear (DSL) and single-stranded (SS) forms were readily discernable in the untreated control ducks (Fig.4 , lane 1 of A, B and G) but the total liver DNA extraction procedure was found to be insensitive for the detection of the supercoiled (SC)form of DHBV. An enrichment technique was necessary to detect this form of DHBV DNA (see later). EcoRI digestion of total liver DNA from the control ducks converted the RC DNA (and any viral SC DNA if present) to the DSL form (Fig. 4 , lane 2 of A, B and G). At the end of treatment with the lower and higher doses of ganciclovir, only a very small amount of RC DNA was observed in a proportion of samples (Fig. 4 , lane 1 of C and D) and in general all the viral replicative intermediates were undetected. EcoRI digestion of the qanciclovlr end of VGElhepatocyte b Table 1 . Effect of gancicloVir therapy on the DHBV-copy number in liver samples of treated versus control ducks.
Duck"
A 5-week-old positive control dose and higher dose ganciclovir ( Fig. 5 lanes 2 and 4) , there was a dramatic reappearance of other DHBV DNA intermediates (presumably the RC and DSL forms) and an increase in the amount of SC DNA to a similar level to that of the controls. Interestingly, with the prednisolone/ganciclovir combination follow-up sample, there was no apparent increase in intensity of the SC DNA band, even though the other intermediates reappeared ( Fig. 5 lane 6) . Prednisolone treatment alone for 2 weeks had no effect on the SC DNAform and the most noticeable influence was to decrease the DSL intermediate ( Fig. 5 lane 7) . As expected, no DHBV DNA forms were detected from the extracted liver sample of the negative control duck ( Fig. 5  lane 10 ).
Discussion treatment samples (Fig. 4 , lane 2 of C and D) detected the presence of DSL viral DNA, which was a consistent finding in these analyses. According to Table 1 there were only 25 VGElcell remaining at the end of treatment; the main contribution to this would appear to be from the RC and SC DHBV DNA. The follow-up specimens revealed the return of all forms of replicative intermediates, i.e. the Re, DSL and SS DNA ( Fig. 4E and F) . No new band or intermediate, possibly linked to the rebound phenomenon, could be detected in these profiles.
Prednisolone treatment for 2 weeks resulted in a decrease in the RC form and an increase in the SS form ( Fig. 4H ). When followed by ganciclovir a similar profile of inhibition was observed except that some low molecular weight intermediates, unaffected by EcoRI digestion, remained (Fig. 41 ). Since inhibition achieved by the sequential treatment (60 VGElcell) was less than that achieved by ganciclovir alone (25 VGE/cell) (Table 1) it is likely that the low molecular weight species probably account for this difference. The profile of the 4-week follow-up sample from the sequential treatment ( Fig. 4J ) was similar to the pattern observed in the 12-week-old control (Fig. 4G ) and ganciclovir follow-up samples ( Fig.  4E and F) .
To determine the amount of DHBV SC DNA, the liver samples from control and treated ducks were processed by a supercoiled DNA selection protocol and analysed by Southern blot hybridization (Fig. 5 ). The only DHBV DNA intermediate detected at the end of treatment with lower dose ganciclovir, higher dose ganciclovir and the prednisolone/ganciclovir combination was the SC DNA species ( Fig. 5 lanes 1, 3 and 5, respectively) . When the amount of the SC DNA was compared to that of the 5-week and 8-week-old control ducks ( Fig. 5 lanes 8 and 9) it was clear that this replicative intermediate was inhibited by the treatments. Soon after cessation of treatment with lower Our results have clearly demonstrated that ganciclovir can inhibit DHBV DNA replication in vivo when used in concentrations similar to those achieved in man in the treatment of cytomegalovirus infections (Jacobsen et al., 1987) . The wider variation in plasma concentrations when higher doses of ganciclovir were used implies that there are saturable rate-limiting step(s) in ganciclovir uptake, metabolism and excretion. Two weeks after cessation of therapy, serum DHBV DNA levels rebounded to pre-treatment values or greater. In other ganciclovir-treated ducks we have observed this rebound phenomenon as early as 5 days following cessation of therapy (results not shown). However, when a course of steroid preceded the ganciclovir treatment, rebound was not observed, but the serum viral DNA level became detectable within 2 weeks of the end of treatment, confirming that relapse had occurred.
anciclovir has been reported to inhibit ground-squirrel hepatitis B virus (Smee et al., 1985) and human HBV (Locarnini et al., 1989) in vivo. In a previous study, Civitico (1990) demonstrated that ganciclovir could significantly and selectively inhibit DHBV DNA replication in primary duck hepatocyte cultures persistently infected with DHBV.This in vitro study also confirmed the observation of Lee et al. (1989) that purine analogues are much more active anti-hepadnaviral agents than Pyrimidine analogues.
Presently, we can only speculate on why purine analogues such as ganciclovir are more effective than their pyrimidine counterparts because little is known about hepatic nucleic acid precursor metabolism. Lee et al. (1989) have suggested three explanations: (i) differences in either cellular uptake or phosphorylation (or both) of purines and pyrimidines; (ii) block of negative-strand DNA synthesis by interference with the attachment site of the protein primer, which is normally covalently linked to a terminal guanine residue within the DR1 repeat sequence (Lienet al., 1987) ;and (iii)interference with the assembly of newly replicated core particles. Of the three, we believe the first may play the major role because recently it has been shown that purine nucleoside analogues can be activated by 5' nucleotidases. These enzymes are widespread in animal tissues and normally catalyse the breakdown of nucleoside 5' monophosphates (Hoglund and Reichard, 1990) . However, Johnson and Fridland (1989) and Ahluwalia et al. (1990) have shown that a 5' nucleotidase from human lymphoid cells can phosphorylate acyclic anddideoxy purine nucleoside analogues usin-g inosine monophosphate (IMP) as the phosphate donor. A similar 5' nucleotidase is abundant in avian liver cytosol and shows a substrate preference for.5' IMP and 5' GMP with negligible activity towards pyrimidine 5' monophosphates (Naito and Tsushima, 1976) . The presence of this enzyme in duck liver would provide a means for activation of ganciclovir and its preference for purines would explain the greater efficacy of purine nucleoside analogues compared to those of pyrimidines.
To determine whether there would be a greater antiviral effect by combining immune stimulation with ganciclovir treatment, we pre-treated three of the ganciclovir-treated ducks with a 2-week course of cortico-steroids (prednisolone). It has been shown previously that steroid withdrawal can produce a transient loss of HBV markers in patients with chronic hepatitis B infection because of an enhanced cellular immune response (Rakela et al., 1983; Hanson et al., 1986) . Also, when steroid therapy was followed by treatment with adenine arabinoside 5'-monophosphate, a much greater efficacy was produced than by treatment with adenine arabinoside 5'-monophosphate alone (Perrillo et aI., 1985) . In the present study, we detected little difference in the level of serum DHBV DNA and DHBsAg or intra-hepatic viral DNA of the combination-treated ducks compared to ganciclovir monotherapy, yet rebound in DHBV viraemia after treatment did not occur. The amount Ganciclovir therapy for hepatitis B virus 111 of viral SO DNA in the liver of the end of treatment combination therapy duck was less than the control and ganciclovir-only treated ducks. The reason(s) for this drop is not clear at present, but further studies are required to clarify possible synergistic interactions between ganciclovir and prednisolone.
Southern blot analysis of the total DNA from the livers of the ganciclovir-treated ducks revealed only trace amounts of viral DNA at the end of treatment. However, this method is unreliable for the detection of the SC form of viral DNA, and the procedure of Wu et al. (1990) was modified to detect this replicative intermediate. The SC DNA analysis demonstrated that this form was the most resistant to treatment. It has been previously recognized,that the SC form of viral DNA is not inhibited by treatment with conventional antiviral agents such as interferon (yokosuka et al., 1985) and that the failure to eliminate hepadnaviral SO DNA is the main reason for the re-initiation of replication following therapy (Sherker et al., 1986; Hirota et al., 1987) . Our studies confirm the durability of this viral intermediate. The half-life and overall persistence of viral SC DNA is emerging as a crucial issue in attempts at chemotherapy for hepadnaviral infections.
Current studies are exploring the use of ganciclovir in combination with SC DNA active compounds such as the prokaryotic DNA gyrase inhibitors which have now been recognized as inhibitors of viral SC DNA generation and processing Locarnini et al., 1990) .
Materials and Experimental procedures

Ducks and treatment protocol
One-day-old Pekin-Aylesbury cross-bred ducks congenitally infected with an Australian strain of DHBV were obtained commercially. Ducklings were bled at 1 week and again at 4 weeks of age. Sera were tested for DHBV DNA by dot-blot hybridization and 18 ducklings which had a stable and intermediate virus titre were chosen for the study. Uninfected t-day-old Pekin-Aylesbury ducklings were obtained from a separate flock known to be free of DHBV (Dixon et al., 1990) . Infected and uninfected birds were housed separately.
Five-week-old ducks were treated with 21-day courses of twice-daily l.p. injections of ganciclovir (Syntex, Palo Alto, CAl or placebo (sterile saline). Ganciclovir was prepared as per manufacturer's instructions. Ducks were assigned to the following treatment regimes: lower dose (10mg/kg/day) ganciclovir (three ducks: Fig. 2A, B, C) , higher dose (30mg/kg/day) ganciclovir (three ducks: Fig. 2 , D, E, F) or prednisolone (Schering, Baulkham Hills, NSW, Australia) treatment for 2 weeks (1 mg/kg once a day) by intramuscular (Lm.) injection, followed by the 21-day lower dose ganciclovir course (3 ducks: Fig. 2, G, H. I) . At the completion of therapy, one of the ducks from each treatment protocol was killed and the liver removed for subsequent analysis. The remaining animals were observed for a 4-week follow-up period after which they were also killed and the livers removed.
Six ducks received equivalent volumes of saline in place of ganciclovir for the course of treatment and acted as controls for serum DHBV DNA. For controls of the other treatment regime, three ducks were treated with prednisolone for 2 weeks, after which one duck was killed and liver tissue removed. The remaining two ducks were treated with saline for a further 3 weeks and followed up for 4 weeks.
In addition to these Control ducks, liver tissue was collected from age-matched 5-week (pre-treatment control), 8-week (end of treatment control) and 12-week-old (follow-up control) DHBV congenitally infected ducks.
Weekly serum specimens were obtained during the treatment period and at 2 weekly intervals during the follow-up period. As well as markers of DHBV replication (see below), blood samples were taken for liver, renal and haematological function tests using standard clinical pathology procedures. The ducks were weighed before, at the end of, and 4 weeks after treatment. Ducks were anaesthetized with sodium pentobarbitone and a large wedge resection from the left and right lobes of the liver was taken. Liver specimens were diced into small pieces and immediately frozen in TNE (50mM Tris-HCI, pH 7.6, 150mM NaCI, 2mM EDTA) and stored at -70°C.
Detection of markers of DHBV replication
DHBV nucleic acids were analysed by molecular hybridization using a full-length DHBV DNA clone in pACYC184 (a gift from Dr Patricia Marion, Stanford University, CAl. The DHBV DNA insert was excised from the plasmid by digestion with EcoRI (Amersham International, Amersham, Bucks, UK), separated by preparative agarose gel electrophoresis and removed by electro elution (Maniatis et al., 1982) . The insert DNA was then purified by ion-exchange chromatography using a NACS prepac column (Bethesda Research Laboratories Life Technologies Inc., Bethesda, MD). DHBV DNA was radiolabelled with [cy_ 3 2p] dATP using a hexamer-primer labelling kit (Bresatec, Adelaide, Australia) to a specific activity of 3 x 10 8-1 x 10 9 c.p.m. per JLg.
Serum markers. Sera were subjected to alkaline denaturation and then tested for DHBV DNA by dot-blot hybridization, as described previously . Serum specimens taken before and at the end of treatment and in the follow up period were also tested for DHBsAg by SPRIA as described by Oiao et al. (1990) . Liver markers. To detect DHBV DNA in liver specimens, two procedures were used.
Total DNA extraction. DNA was extracted from livers and analysed by dot-blot and Southern blot hybridization according to the protocol of Bishop et al. (1990) . Briefly, 300 mg of liver tissue were homogenized in TNE and the crude homogenate digested with 500 JLg/ml pronase for 1hat 3rC in the presence of 1% SDS. The total cellular DNA was prepared by two phenol/chloroform extractions (1: 1), precipitated with ethanol, redissolved in TE (10mM Tris-HCI, pH 7.6, 2mM EDTA) and then treated with 25 JLg/ml pancreatic RNase A (Boehringer-Mannheim, Mann" heim, Germany) for 1h at 37"C. After digestion, the DNA was extracted again with phenol/chloroform, precipitated with ethanol, washed four times in 70% ethanol and then dissolved in distilled water.
For dot-blot hybridization analysis, standardized amounts of cellular DNA (1.0 JLg) of each sample were tested directly and in doubling dilutions out to 1 : 128. Before Southern blot hybridization, samples of viral DNA were either left untreated or digested with EcoRI for 2h at 37"C. Total cellular DNA (1OJLg, uncut or Eco RI cut) was subjected to gel electrophoresis in 1% agarose, denatured and neutralized, and transferred by vacuum to a nylon membrane (GeneScreen Plus, DuPont, MA).
Supercoiled viral DNA extraction. Supercoiled (SC) viral DNA was extracted from liver tissue after homogenization using a modification of the method of Wu et al. (1990) . Liver tissue was homogenized in 10mM Tris-HCI (pH 7.6), 10mM EDTA and then SDS and KCI were added to a final concentration of 0.5% and 0.5M, respectively. The resulting cloudy suspension was clarified by centrifugation for 20 min at 10000g using a JA-20 rotor in a Beckman J2 centrifuge. The clear supernatant containing SC DNA was extracted twice with an equal volume of phenol saturated with 50mM Tris-HCI (pH 7.6) and once with an equal volume of 'Iris-saturated phenol/chloroform. DNA was precipitated with ethanol, washed twice with 70% ethanol and redissolved in TE. Prior to Southern blot hybridizaton, DNA was transferred to a nylon membrane after gel electrophoresis as described above.
Hybridization conditions
The hybridization solution for nitrocellulose membranes consisted of 50% deionized formamide, 5 x SSC (1 x SSC is 0.15 M NaCI, 0.015M sodium citrate, pH 7.0), 2 x Denhardt solution, 5 mM sodium phosphate (pH 6.5) and 100 JLg/ml denatured herring sperm DNA. For nylon membranes, the hybridization solution was the same except that SDS was added to 'a final concentration of 1%. Heat-denatured radiolabelled probe was added to a concentration of at least 2 x 10 6 c.p.m.lml and the hybridization proceeded overnight at 42°C. After hybridization, membranes were washed twice in 2 x SSC/O.1 % SDS for 5 min each at room temperature and twice with 0.1 x SSC/O.1 % SDS for 30 min each at 50°C. Radiolabelled DNA was detected by exposure of the membrane to X-Omat RP film (Eastman-Kodak, Rochester, NY) between intensifying screens.
Pharmaco~neticana~ses
Plasma concentrations of ganciclovir were monitored in a separate study using 8 age-matched ducks similar to those used in the treatment protocols described above. Blood was obtained from leg veins and anti-coagulated with heparin (0.5 units per ml blood). Samples were taken immediately before i.p, injection of lower dose or higher dose ganciclovir and at intervals thereafter during the next 6h. Four ducks were used for each ganciclovir dose. Plasma was immediately prepared from each blood sample and plasma protein was precipitated with 2.5% perchloric acid, then removed by centrifugation. Supernatants were neutralized with 2 M ammonium bicarbonate and analysed by HPLC. HPLC analyses were performed using a Waters Nova Pak C18 reversephase cartridge column (dimensions 8 mm x 10 cm, particle size 4 JLm). Samples were eluted isocratically at a flow rate of 2.0ml/min with 5% (v/v) methanol in 20mM ammonium acetate, pH 3.0. The eluant was monitored for UV absorption at 255nm.
The detector was connected to a recording integrator, permitting automatic calibration and peak analysis. Plasma ganciclovir concentrations were estimated by reference to standards prepared by spiking pre-treatment plasma with known concentrations of ganciclovir. Recovery of ganciclovir from spiked samples averaged 97%.
